Search Result

Results for "

ABT

" in MedChemExpress (MCE) Product Catalog:

By Targets:	11β-HSD (1) Acyltransferase (1) Adenosine Kinase (4) Adenosine Receptor (2) Adrenergic Receptor (5) Akt (2) Amylases (1) Antibiotic (5) Antibody-Drug Conjugates (ADCs) (2) Apoptosis (20) Aurora Kinase (2) Autophagy (15) Bacterial (10) Bcl-2 Family (13) Biochemical Assay Reagents (3) c-Fms (3) c-Kit (3) c-Met/HGFR (3) Calcium Channel (2) CCR (1) Cholinesterase (ChE) (5) COX (3) Cytochrome P450 (3) DNA/RNA Synthesis (4) Dopamine Receptor (6) Drug Derivative (6) Drug Intermediate (1) Drug Metabolite (2) Dynamin (1) EGFR (2) Endogenous Metabolite (1) Endothelin Receptor (3) Environmental Pollutants (1) Estrogen Receptor/ERR (1) Farnesyl Transferase (1) Ferroptosis (1) FLT3 (3) Glycosidase (3) HCV (15) HCV Protease (6) HDAC (1) Histamine Receptor (3) HIV (11) HIV Protease (11) HSP (1) HSV (1) IFNAR (1) iGluR (1) Interleukin Related (7) Isotope-Labeled Compounds (13) JAK (4) LDLR (1) Leukotriene Receptor (1) Ligands for Target Protein for PROTAC (2) Lipoxygenase (2) Melanocortin Receptor (2) Microtubule/Tubulin (4) Mitophagy (1) MMP (3) Molecular Glues (3) nAChR (18) NEKs (3) NO Synthase (1) Notch (1) PARP (5) PDGFR (6) Platelet-activating Factor Receptor (PAFR) (1) PPAR (2) Proteasome (3) Reactive Oxygen Species (ROS) (5) Reference Standards (24) SARS-CoV (16) SF3B1 (1) Small Interfering RNA (siRNA) (1) TGF-beta/Smad (1) TNF Receptor (2) Toll-like Receptor (TLR) (1) Trk Receptor (1) TRP Channel (5) Tyrosinase (2) VEGFR (7) VZV (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (61) Cardiovascular Disease (10) Endocrinology (9) Infection (35) Inflammation/Immunology (47) Metabolic Disease (9) Neurological Disease (44)
Oligonucleotides:	Human Pre-designed siRNA Sets (1) Polymers (1) siRNAs (1)

197

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15531

Venetoclax Maximum Cited Publications 227 Publications Verification ABT-199; GDC-0199; RG7601	Bcl-2 Family Autophagy	Cancer
Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a K_i of less than 0.01 nM. Venetoclax induces autophagy .

HY-10087

Navitoclax 145+ Cited Publications ABT-263	Bcl-2 Family	Cancer
Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-x_L, Bcl-2 and Bcl-w, with a K_i of less than 1 nM .

HY-19569

Upadacitinib 25+ Cited Publications ABT-494	JAK	Inflammation/Immunology
Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-50907

ABT-737 65+ Cited Publications	Bcl-2 Family Apoptosis Autophagy Mitophagy	Inflammation/Immunology Cancer
ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .

HY-10129

Veliparib 45+ Cited Publications ABT-888	PARP Autophagy	Cancer
Veliparib (ABT-888) is a potent PARP inhibitor, inhibiting PARP1 and PARP2 with K_is of 5.2 and 2.9 nM, respectively .

HY-90001

Ritonavir 30+ Cited Publications ABT 538; RTV	HIV Protease HIV SARS-CoV Apoptosis	Infection Neurological Disease Inflammation/Immunology Cancer
Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM. Ritonavir (ABT 538) can penetrate the blood brain barrier (BBB) .

HY-103389

1-Aminobenzotriazole 5+ Cited Publications ABT; 3-Aminobenzotriazole	Cytochrome P450	Cancer
1-Aminobenzotriazole is a nonspecific and irreversible inhibitor of cytochrome P450 (P450).

HY-103161

ABT-702 dihydrochloride 3 Publications Verification	Adenosine Kinase	Inflammation/Immunology
ABT-702 dihydrochloride is a potent adenosine kinase (AK) inhibitor (IC₅₀=1.7 nM).

HY-14588

Lopinavir 15+ Cited Publications ABT-378	HIV HIV Protease SARS-CoV	Infection Neurological Disease Cancer
Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-50751

Linifanib 5 Publications Verification ABT-869; AL-39324	PDGFR VEGFR FLT3 c-Fms c-Kit Autophagy Apoptosis	Cancer
Linifanib (ABT-869) is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC₅₀s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib shows prominent antitumor activity. Linifanib has much less activity against unrelated RTKs, soluble tyrosine kinases, or serine/threonine kinases. Linifanib is a specific miR-10b inhibitor that blocks miR-10b biogenesis .

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P99391

Telisotuzumab ABT-700; ABBV-400 Antibody	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-12594

Paritaprevir 10+ Cited Publications ABT-450; Veruprevir	HCV Protease HCV SARS-CoV	Infection
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC₅₀s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor) .

HY-13270

ABT-751 E7010	Microtubule/Tubulin Autophagy Apoptosis	Cancer
ABT-751 (E7010) is a novel, highly orally bioavailable sulfonamides antimitotic compound and tubulin binder. It prevents tubulin aggregation by binding to the colchicine site on β-tubulin, leading to cell cycle arrest in G2/M phase and inducing apoptosis, thus effectively preventing cell division. ABT-751 induces autophagy by inhibiting the AKT/MTOR signaling pathway. ABT-751 showed significant inhibition against various types of cancer cells, including lung, gastric, colon, and breast cancer .

HY-15403

Atrasentan 5+ Cited Publications ABT-627; (+)-A 127722; A-147627	Endothelin Receptor	Cardiovascular Disease Endocrinology Cancer
Atrasentan (ABT-627) is an endothelin receptor antagonist with IC₅₀ of 0.0551 nM for ET_A .

HY-13998

Dasabuvir 10+ Cited Publications ABT-333	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) is a nonnucleoside hepatitis C virus (HCV) polymerase inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-14739

Choline Fenofibrate 3 Publications Verification ABT-335	PPAR COX	Cardiovascular Disease
Choline Fenofibrate (ABT-335), a choline salt of Fenofibric acid (HY-B0760), releases free Fenofibric acid in the gastrointestinal tract. Fenofibric acid is a PPAR activator with antihyperlipidemic effect .

HY-P99721

Lutikizumab ABT-981	Interleukin Related	Inflammation/Immunology
Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .

HY-44432

Navitoclax-piperazine ABT-263-piperazine	Ligands for Target Protein for PROTAC Bcl-2 Family	Cancer
Navitoclax-piperazine (ABT-263-piperazine) is a Navitoclax (HY-10087) analog and BCL-XL inhibitor. Navitoclax-piperazine is the ligand for target protein of PROTAC DT2216 (HY-130604). Navitodax-pperaie and E3 ubiquitin ligase VHL ligand can be used to synthesize PROTAC DT2216 (HY-130604) .

HY-15531R

Venetoclax (Standard) ABT-199 (Standard); GDC-0199 (Standard); RG7601 (Standard)	Reference Standards Bcl-2 Family Autophagy	Cancer
Venetoclax (Standard) is the analytical standard of Venetoclax. This product is intended for research and analytical applications. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a K_i of less than 0.01 nM. Venetoclax induces autophagy .

HY-112482

ABT-702 3 Publications Verification	Adenosine Kinase Adenosine Receptor	Neurological Disease Inflammation/Immunology
ABT-702 (Adenosine Kinase Inhibitor) is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC₅₀ of 1.7 nM. ABT-702 shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 shows analgesic and anti-inflammatory effects in vivo. ABT-702 can be used for diabetic retinopathy research .

HY-19569R

Upadacitinib (Standard) 1 Publications Verification ABT-494 (Standard)	Reference Standards JAK	Inflammation/Immunology
Upadacitinib (Standard) is the analytical standard of Upadacitinib. This product is intended for research and analytical applications. Upadacitinib (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-15403A

Atrasentan hydrochloride 5+ Cited Publications ABT-627 hydrochloride; (+)-A 127722 hydrochloride; A-147627 hydrochloride	Endothelin Receptor	Cardiovascular Disease Endocrinology Cancer
Atrasentan hydrochloride (ABT-627 hydrochloride) is a selective endothelin A receptor antagonist with an IC₅₀ of 0.0551 nM for ET_A .

HY-12424

Zotarolimus 4 Publications Verification ABT-578; A 179578	Drug Derivative	Cardiovascular Disease Inflammation/Immunology Cancer
Zotarolimus (ABT-578) is a derivative of Rapamycin (HY-10219), with anti-proliferative activity. Zotarolimus is an immunosuppressant. Zotarolimus is developed specifically for local delivery from stents for the prevention of coronary artery restenosis .

HY-132259

Depatuxizumab mafodotin 1 Publications Verification ABT-414	Antibody-Drug Conjugates (ADCs) EGFR	Cancer
Depatuxizumab mafodotin (ABT-414) is an antibody-drug conjugate (ADC). Depatuxizumab mafodotin specifically targets the epidermal growth factor receptor (EGFR). Depatuxizumab mafodotin can be used in the study of glioma, head and neck squamous cell carcinoma, non-small cell lung cancer, epidermoid carcinoma of the skin, and squamous cell carcinoma of the tongue .

HY-112482A

ABT-702 hydrochloride 3 Publications Verification	Adenosine Kinase Adenosine Receptor	Neurological Disease Inflammation/Immunology
ABT-702 hydrochloride is a potent, orally active, and selective adenosine kinase (AK) inhibitor with an IC₅₀ of 1.7 nM. ABT-702 hydrochloride shows >1300-fold selectivity for AK over other biological targets, including cyclooxygenases-1 and -2. ABT-702 hydrochloride attenuates inflammation in diabetic retinopathy by increasing free adenosine levels. ABT-702 hydrochloride shows analgesic and anti-inflammatory effects in vivo. ABT-702 hydrochloride can be used for diabetic retinopathy research .

HY-109001

Alicapistat 1 Publications Verification ABT-957	Proteasome	Neurological Disease
Alicapistat (ABT-957) is an orally active selective inhibitor of human calpains 1 and 2 for the potential application of Alzheimer's disease (AD) . Alicapistat mitigates the metabolic liability of carbonyl reduction and inhibits calpain 1 with an IC₅₀ value of 395 nM .

HY-13545

ABT-510 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-14824

Sofiniclin ABT 894	nAChR	Neurological Disease
Sofiniclin (ABT 894), an agonist of nicotinic acetylcholine receptor (nAChR), is used as a potential non-stimulant research for attention-deficit/hyperactivity disorder (ADHD) .

HY-16018A

Ilorasertib hydrochloride ABT-348 hydrochloride	Aurora Kinase PDGFR VEGFR	Cancer
Ilorasertib (ABT-348) hydrochloride is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib hydrochloride also is a potent VEGF, PDGF inhibitor. Ilorasertib hydrochloride has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-16018

Ilorasertib ABT-348	Aurora Kinase VEGFR PDGFR	Cancer
Ilorasertib (ABT-348) is a potent, orally active and ATP-competitive aurora inhibitor with IC₅₀s of116, 5, 1 nM for aurora A, aurora B, aurora C, respectively. Ilorasertib also is a potent VEGF, PDGF inhibitor. Ilorasertib has the potential for the research of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) .

HY-P990312

ABT-325	Interleukin Related	Inflammation/Immunology
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-13545B

ABT-510 acetate 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-19721

ABT-639 3 Publications Verification	Calcium Channel	Neurological Disease
ABT-639 is a novel, peripherally acting, selective T-type Ca ²⁺ channel blocker.

HY-12195

ABT-239 2 Publications Verification	Histamine Receptor TRP Channel	Neurological Disease Endocrinology
ABT-239 is a novel, highly efficacious, non-imidazole class of H3R antagonist and a transient receptor potential vanilloid type 1 (TRPV1) antagonist.

HY-117853

Atreleuton ABT-761; VIA-2291	Lipoxygenase	Cardiovascular Disease
Atreleuton (ABT-761) is a selective, reversible, and orally bioavailable 5-Lipoxygenase (5-LO) inhibitor. Atreleuton (ABT-761) exhibits potent and selective inhibition of leukotriene formation . Atreleuton is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-101634

ABT-072	HCV	Infection
ABT-072 is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-110160

Pozanicline dihydrochloride ABT-089 dihydrochloride	nAChR	Neurological Disease
Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a K_i of 16.7 nM for binding to [ ³H]cytisine sites . Pozanicline is an α4β2-selective nAChR agonist, which binds to rat brain α4β2 nAChR with a K_i of 17 nM while binding to α7 nAChR is insignificant .

HY-10087R

Navitoclax (Standard) ABT-263 (Standard)	Reference Standards Bcl-2 Family	Cancer
Navitoclax (Standard) is the analytical standard of Navitoclax. This product is intended for research and analytical applications. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .

HY-W727879

Upadacitinib-15N,d2 1 Publications Verification ABT-494-¹⁵N,d₂	Isotope-Labeled Compounds	Others
Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-108038

ABT-107	nAChR	Neurological Disease
ABT-107 is a selective α7 neuronal nicotinic receptor agonist. ABT-107 protects against nigrostriatal damage in rats with unilateral 6-hydroxydopamine lesions .

HY-103409

ABT-724 trihydrochloride	Dopamine Receptor	Neurological Disease
ABT-724 trihydrochloride is a potent and highly selective dopamine D₄ receptor agonist with an EC₅₀ of 12.4 nM for human dopamine D₄ receptor. ABT-724 trihydrochloride is a potent partial agonist at the rat D₄ (EC₅₀ of 14.3 nM) and the ferret D₄ receptor (EC₅₀ of 23.2 nM), and has no effect on dopamine D₁, D₂, D₃, or D₅ receptors. ABT-724 trihydrochloride could be useful for the treatment of erectile dysfunction and has favorable side-effect profile .

HY-118956

Adrogolide hydrochloride ABT-431 hydrochloride; DAS-431 hydrochloride	Dopamine Receptor	Neurological Disease
Adrogolide hydrochloride (ABT-431 hydrochloride) is a chemically stable prodrug that can convert to the dopamine D1 receptor agonist A-86929. Adrogolide hydrochloride ameliorates the MPTP (HY-15608)-induced Parkinson's Disease in marmoset model, reduces the dyskinesias tendency. Adrogolide hydrochloride reverses Risperidone (HY-11018)-induced cognitive deficits in monkey .

HY-111262

ABT-384	11β-HSD	Neurological Disease Metabolic Disease
ABT-384 is a potent, selective 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor. ABT-384 exhibits high affinity (K_i 0.1-2.7 nM) against rodent, monkey, and human 11β-HSD1. ABT-384 blocks regeneration of active cortisol. ABT-384 can be used for the research of Alzheimer’s disease (AD) .

HY-119257

ABT-100 1 Publications Verification	Farnesyl Transferase Apoptosis	Cancer
ABT-100, a chemical probe, is a potent, highly selective and orally active farnesyltransferase inhibitor. ABT-100 inhibits cell proliferation (IC₅₀s of 2.2 nM, 3.8 nM, 5.9 nM, 6.9 nM, 9.2 nM, 70 nM and 818 nM for EJ-1, DLD-1, MDA-MB-231, HCT-116, MiaPaCa-2, PC-3, and DU-145 cells, respectively), increases apoptosis and decreases angiogenesis. ABT-100 possesses broad-spectrum antitumor activity .

HY-15197

ABT-046	Acyltransferase	Metabolic Disease
ABT-046 is a potent, selective, and orally active acyl CoA:diacylglycerol acyltransferase 1 (DGAT-1) inhibitor with IC₅₀s of both 8 nM against human and mouse DGAT-1 .

HY-19569S1

Upadacitinib-d5 ABT-494-d₅	Isotope-Labeled Compounds JAK	Inflammation/Immunology
Upadacitinib-d₅ (ABT-494-d₅) is the deuterium labeled Upadacitinib (HY-19569). Upadacitinib (ABT-494) is a potent, orally active and selective JAK1 inhibitor (IC₅₀ = 43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-101634A

ABT-072 potassium trihydrate	HCV	Infection
ABT-072 (potassium trihydrate) is an orally active and potent non-nucleoside HCV NS5B polymerase inhibitor (HCV GT1a EC₅₀=1 nM; HCV GT1b EC₅₀=0.3 nM) .

HY-16748

Nelonicline ABT-126	nAChR	Neurological Disease
Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease .

HY-U00399A

Fiduxosin hydrochloride ABT 980	Adrenergic Receptor	Endocrinology
Fiduxosin hydrochloride (ABT 980) is a potent α1-adrenoceptor antagonist, with K_i of 0.160 nM, 24.9 nM, and 0.920 nM for α1a-, α1b-, and α1d-adrenoceptors, respectively .

Cat. No.	Product Name	Type

HY-141601

Telisotuzumab vedotin

2 Publications Verification

ABBV-399

Fluorescent Dyes

Telisotuzumab vedotin (ABBV-399) (Teliso-V) is an anti-c-Met antibody-drug conjugate. Telisotuzumab vedotin consists of an anti-c-Met monoclonal antibody Telisotuzumab (ABT-700) (HY-P99391) and Monomethyl Auristatin E (HY-15162). Telisotuzumab vedotin exerts antitumor activity with acceptable toxicity in vivo. Telisotuzumab vedotin can be used for non-small cell lung cancer (NSCLC) research .

HY-50751G

Linifanib

ABT-869; AL-39324

Fluorescent Dyes

Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC₅₀s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells .

Cat. No.	Product Name	Type

HY-50751G

Linifanib

ABT-869; AL-39324

Biochemical Assay Reagents

Cat. No.	Product Name	Target	Research Area

HY-13545

ABT-510 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-13545B

ABT-510 acetate 1 Publications Verification	Apoptosis	Inflammation/Immunology Cancer
ABT-510 acetate is an anti-angiogenic TSP peptide (Thrombospondin-1 analogue) that induces apoptosis and inhibits ovarian tumour growth in an orthotopic, syngeneic model of epithelial ovarian cancer. ABT-510 acetate also reduces angiogenesis and inflammatory responses in a murine model of inflammatory bowel disease. ABT-510 acetate can be used in studies of cancer (particularly epithelial ovarian cancer) and inflammatory bowel disease (IBD) .

HY-105305

Modimelanotide ABT-719; AP-214	Melanocortin Receptor	Inflammation/Immunology
Modimelanotide (ABT-719) is an α-melanocyte-stimulating hormone analog. Modimelanotide has high specific binding ability to melanocortin receptors (MCR1, 3, 4, 5). Modimelanotide possesses anti-inflammatory and organ-protective effects. Modimelanotide can be used in the research of diseases such as acute kidney injury .

HY-P5317

MAQAAEYYR	Reactive Oxygen Species (ROS)	Inflammation/Immunology
MAQAAEYYR is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MAQAAEYYR has high DPPH, ABTS radical and ROS-scavenging ability. MAQAAEYYR protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-P5316A

MHLWAAK TFA	Peptides	Inflammation/Immunology
MHLWAAK TFA is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MHLWAAK TFA has high DPPH and ABTS radical scavenging ability. MHLWAAK TFA protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-P5318

MDYYFEER	Reactive Oxygen Species (ROS)	Inflammation/Immunology
MDYYFEER is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MDYYFEER has high DPPH and ABTS radical scavenging ability. MDYYFEER protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-P5317A

MAQAAEYYR TFA	Reactive Oxygen Species (ROS)	Inflammation/Immunology
MAQAAEYYR TFA is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MAQAAEYYR TFA has high DPPH, ABTS radical and ROS-scavenging ability. MAQAAEYYR TFA protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-P5318A

MDYYFEER TFA	Peptides	Inflammation/Immunology
MDYYFEER TFA is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MDYYFEER TFA has high DPPH and ABTS radical scavenging ability. MDYYFEER TFA protects zebrafish larvae from H₂O₂-induced oxidative damage .

HY-105305A

Modimelanotide acetate ABT-719 acetate; AP-214 acetate	Melanocortin Receptor	Endocrinology
Modimelanotide (ABT-719) acetate is an α-melanocyte-stimulating hormone analog. Modimelanotide acetate has high specific binding ability to melanocortin receptors (MCR1, 3, 4, 5). Modimelanotide acetate possesses anti-inflammatory and organ-protective effects. Modimelanotide acetate can be used in the research of diseases such as acute kidney injury .

HY-P5316

MHLWAAK	Peptides	Inflammation/Immunology
MHLWAAK is an antioxidant active peptide that can be isolated from pancreatin hydrolysate of C-phycocyanin. MHLWAAK has high DPPH and ABTS radical scavenging ability. MHLWAAK protects zebrafish larvae from H₂O₂-induced oxidative damage .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99486

Briakinumab ABT-874	Interleukin Related	Inflammation/Immunology
Briakinumab (ABT-874) is a fully human anti-IL-12/23p40 monoclonal antibody. Briakinumab targets and neutralizes IL-12 and IL-23. Briakinumab can be used for the research of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis .

HY-P99391

Telisotuzumab ABT-700; ABBV-400 Antibody	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-P99361

Enavatuzumab PDL192; ABT-361; Anti-TNFRSF12A/TWEAKR/CD266 Reference Antibody (enavatuzumab)	TNF Receptor	Cancer
Enavatuzumab (PDL192; ABT-361) is a humanized IgG1 monoclonal antibody targeting the receptor of TNF-like weak inducer of apoptosis (TWEAK). TWEAK (Fn14; TNFRSF12A), the natural ligand of the TWEAK receptor (TweakR), stimulates multiple cellular responses. Enavatuzumab induces tumor growth inhibition through direct TweakR signaling and antibody dependent cell-mediated cytotoxicity (ADCC). Enavatuzumab can actively recruits and activates myeloid effectors to kill tumor cells. Enavatuzumab inhibits the growth of various human TweakR-positive cancer cell lines and xenografts in vitro and in vivo .

HY-P99849

Depatuxizumab ABT-806	EGFR	Cancer
Depatuxizumab is a brain-penetrant and humanized tumor-specific anti EGFR monoclonal antibody. Depatuxizumab inhibits the growth of xenograft models of mutant EGFRvIII and wild-type EGFR. Depatuxizumab can be used for research on cancer .

HY-P99721

Lutikizumab ABT-981	Interleukin Related	Inflammation/Immunology
Lutikizumab (ABT-981) is an anti-IL-1α and IL-1β dual variable domain immunoglobulin. Lutikizumab binds and inhibits IL-1α and IL-1β. Lutikizumab can be used for the research of osteoarthritis .

HY-P99496

Cendakimab 1 Publications Verification RPC 4046; ABT 308; CC-93538	Interleukin Related	Inflammation/Immunology
Cendakimab (RPC4046; ABT 308; CC-93538) is a selective, humanized, recombinant monoclonal antibody against the IL-13 molecule. Cendakimab has a high affinity and potency for both human wild-type and variant IL-13 and blocks binding of IL-13 to both IL-13Rα1 and IL-13Rα2 with IC₅₀s of 352 pM and 631 pM by ELISA, respectively. Cendakimab recognizes both wild-type human IL-13 and the common polymorphic variant R110Q, with binding affinities of 52 and 50 pM, respectively. Cendakimab has the potential for IL-13-related allergic/inflammatory diseases (e.g., asthma and eosinophilic esophagitis) .

HY-P99359

Elezanumab ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)	TGF-beta/Smad	Metabolic Disease
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC₅₀ around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .

HY-P99627

Frunevetmab NV-02; PG110; ABT-110	Trk Receptor	Inflammation/Immunology
Frunevetmab (NV-02) is a felinized anti-nerve growth factor (NGF) monoclonal antibody with a K_d of 20 pM. Frunevetmab can effectively decrease osteoarthritis (OA) pain in cats .

HY-P99852

Dilpacimab ABT165; PR1283233	VEGFR Notch	Cancer
Dilpacimab (ABT165) is a bispecific variable domain immunoglobulin. Dilpacimab binds to and inhibits DLL4 and VEGF and acts as a tumor growth inhibitor. Dilpacimab can be used in research related to metastatic colorectal cancer and advanced solid tumors .

HY-P99940

Remtolumab ABT-122	TNF Receptor Interleukin Related	Inflammation/Immunology
Remtolumab is a bispecific variable domain immunoglobulin molecule with human affinities for TNFα and IL-17 in the low pM range of K_d. Remtolumab can be used in research related to rheumatoid arthritis, psoriatic arthritis, and moderate-to-severe plaque psoriasis .

HY-P990312

ABT-325	Interleukin Related	Inflammation/Immunology
ABT-325 is a humanized antibody expressed in CHO that targets IL-18. ABT-325 has a huIgG1 type heavy chain and a huκ type light chain, with a predicted molecular weight (MW) of 146.28 kDa. The isotype control for ABT-325 can refer to Human IgG1 kappa, Isotype Control (HY-P99001).

HY-P991611

ART5803	iGluR	Inflammation/Immunology
ART5803 is a humanized IgG1 monoclonal antibody inhibitor targeting NMDAR. ART5803 binds to the N-terminal domain (NTD) of the NMDAR GluN1 subunit (GluN1-NTD) with a high affinity. ART5803 blocks NMDAR internalization induced by pathogenic autoantibodies and restores cell-surface NMDAR expression and functions. ART5803 reverses behavioral abnormalities and NMDAR expression in marmoset disease models. ABT-147 can be used to study anti-NMDAR encephalitis .

HY-P99391A

Telisotuzumab (powder) ABT-700 (powder)	c-Met/HGFR Apoptosis	Cancer
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .

HY-P991941

ABT-182	CCR	Inflammation/Immunology
ABT-182 is an antibody against human CCR8.

HY-P991593

ABT-147	Interleukin Related	Inflammation/Immunology
ABT-147 is a humanized IgG1 monoclonal antibody inhibitor targeting IL-12. ABT-147 can be used to study autoimmune diseases like rheumatoid arthritis (RA), inflammatory diseases like inflammatory bowel disease (IBD) and other diseases like Asthma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0778

Isorhamnetin-3-O-neohespeidoside 3 Publications Verification	Flavonols Flavonoids Typhaceae Classification of Application Fields Typha angustifolia L. Phenols Polyphenols Plants Disease Research Fields Source Classification Cancer	Xanthine Oxidase
Isorhamnetin-3-O-neohespeidoside is a flavonoid. Isorhamnetin-3-O-neohespeidoside can be isolated from Typha angustifolia. Isorhamnetin-3-O-neohespeidoside inhibits xanthine oxidase activity with an IC₅₀ of 48.75 μg mL. Isorhamnetin-3-O-neohespeidoside has antioxidant and osteoclastogenic activities. Isorhamnetin-3-O-neohespeidoside can be used in research of bone .

HY-N0627

Kaempferol-7-O-β-D-glucopyranoside	Flavonols Structural Classification Flavonoids other families Classification of Application Fields Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Source Classification	LDLR
Kaempferol-7-O-β-D-glucopyranoside is a flavonoid glycoside. Kaempferol-7-O-β-D-glucopyranoside exists in the root bark of Cudrania tricuspidata. Kaempferol-7-O-β-D-glucopyranoside inhibits Cu ²⁺-induced lipid peroxidation of low-density lipoprotein. Kaempferol-7-O-β-D-glucopyranoside possesses antioxidant activity and scavenges DPPH free radicals .

HY-N7627

Regaloside C	Cardiovascular Disease Structural Classification Classification of Application Fields Simple Phenylpropanols Gramineae Secale cereale Phenols Polyphenols Phenylpropanoids Plants Disease Research Fields Source Classification	Estrogen Receptor/ERR Toll-like Receptor (TLR) Akt MMP HSP
Regaloside C is an anti-inflammatory agent and antioxidant that scavenges ABTS and DPPH free radicals. Regaloside C targets multiple molecules including TNF-α, MMP-2, ERα, AKT1, TLR4 and HSP90-α. Regaloside C is applicable to research related to inflammatory diseases .

HY-N8194

Syringetin-3-O-glucoside Syringetin 3-O-β-D-glucoside	Flavonols Flavonoids Vitis vinifera cv. Zalema Phenols Polyphenols Plants Vitaceae Source Classification	Others
Syringetin-3-O-glucosid (Syringetin 3-O-β-D-glucoside), a flavonol glycoside, shows relatively weak DPPH and ABTS radical scavenging activity .

HY-156711

Ternatumoside II	Flavonoids Flavones Crassulaceae Plants Rhodiola crenulata (HK. f. et.Thoms) H. Ohba Source Classification	IFNAR
Ternatumoside II is a flavonoid glycoside that can be isolated from R. crenulata. Ternatumoside II can stimulate IFN-γ expression. Ternatumoside II has radical-scavenging activities (IC₅₀s: 260.5 μM and 320.2 μM for DPPH and ABTS) .

HY-N12291

7,4'-Dihydroxyhomoisoflavane	Monophenols Phenols Plants Source Classification Asparagaceae Juss.	Others
7,4'-Dihydroxyhomoisoflavane is a natural antioxidant. 7,4'-Dihydroxyhomoisoflavane has ABTS radical-scavenging capacity with an IC₅₀ of 0.22 mg/mL .

HY-N10770

5'-Geranyl-5,7,2',4'-tetrahydroxyflavone	Flavonoids Gramineae Plants Other Flavonoids Saccharum officinarum Source Classification	Others
5'-Geranyl-5,7,2',4'-tetrahydroxyflavone, a phenolic compound, presents strong oxygen radical absorbance capacity (ORAC), DPPH radical-scavenging capacity, ABTS radical-scavenging capacity, ferric reducing antioxidant power (FRAP) and nitrite-scavenging capacity. 5'-Geranyl-5,7,2',4'-tetrahydroxyflavone has the potential for natural antioxidant research .

HY-N11997

Feralolide	Liliaceae Coumarins Phenols Polyphenols Aloe vera (L.) Burm. f. Phenylpropanoids Plants Source Classification	Cholinesterase (ChE)
Feralolide is a dihydroisocoumarin isolated from the methanolic extract of aloe vera resin. Feralolide is also a dual inhibitor of AChE and BuChE, with IC₅₀s of 55 μg/mL and 52 μg/mL respectively. Feralolide has antioxidant activity and inhibits 2,2-diphenyl-1-picrylhydrazyl (DPPH) and 2, 2′-azinobis-3-ethylbenzothiazoline-6-sulfonic acid (ABTS). Feralolide could be used in research into cognitive disorders such as Alzheimer's disease, potentially restoring and enhancing memory .

HY-N17925

Falandioside B	Structural Classification Rosaceae Phenols Polyphenols Plants Fragaria × ananassa Duch. Source Classification	Glycosidase
Falandioside B is an α-glucosidase inhibitor with an IC₅₀ of 107.52 μM. Falandioside B scavenges ABTS radical cations. Falandioside B is applicable to research related to postprandial hyperglycemia .

HY-N19783

Carambolaside M	Structural Classification Polysaccharides Averrhoa carambola L. Plants Oxalidaceae Saccharides Source Classification	Drug Derivative
Carambolaside M acts as an ABTS radical cation scavenger. Carambolaside M scavenges ABTS radical cations. Carambolaside M is isolated from the fresh sweet fruits of Averrhoa carambola L., a plant belonging to the genus Averrhoa in the Oxalidaceae family .

HY-N18052

Massonianoside E	Structural Classification Viburnaceae Lignans Phenylpropanoids Plants Viburnum rhytidophyllum Hemsl. Source Classification	Others
Massonianoside E is an antioxidant that has been found to be present in the fruits of Viburnum rhytidophyllum Hemsl. Massonianoside E can exert antioxidant activity in DPPH, ABTS and PTIO assays .

HY-N18281

Hazelnutin F	Structural Classification Alkaloids Plants Betulaceae Corylus avellana L. Indole Alkaloids Source Classification	Drug Derivative
Hazelnutin F is an indoleacetic acid glycoside found in the kernels of Corylus avellana L.. Hazelnutin F lacks significant antioxidant activity against ABTS and DPPH radicals .

HY-N17733

4,5-O-Dicaffeoylquinic acid ethyl ester	Structural Classification Chrysanthemum × morifolium (Ramat.) Hemsl. Asteraceae Phenols Polyphenols Plants Compositae Saussurea involucrata (Kar. et Kir.) Sch.-Bip. Source Classification	Others
4,5-O-Dicaffeoylquinic acid ethyl ester is an ABTS free radical scavenger with an IC₅₀ of 5.95 μM. 4,5-O-Dicaffeoylquinic acid ethyl ester shows no antibacterial activity against Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. 4,5-O-Dicaffeoylquinic acid ethyl ester can be used in liver injury protection studies .

HY-N16851

Breynioside A	Structural Classification Verbenaceae Phenols Plants Vitex negundo var. heterophylla (Franch.) Rehder Source Classification	Drug Derivative
Breynioside A is a natural phenolic compound.

HY-N9229

Myricadenin A	Structural Classification Natural Products Other Phenylpropanoids Phenylpropanoids Plants Morella adenophora (Hance) J. Herb. Source Classification Myricaceae	NO Synthase Bacterial
Myricadenin A is an iNOS inhibitor, capable of effectively inhibiting the production of NO (EC₅₀ = 18.1 μM). Myricadenin A has moderate ABTS free radical scavenging activity (SC₅₀ = 175.4 μM) and relatively weak anti-tuberculosis activity (MIC = 80.0 μg/mL). Myricadenin A can be used in inflammation-related research .

Cat. No.	Product Name	Chemical Structure

HY-15531S

Venetoclax-d8
Venetoclax-d₈ is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a K_i of less than 0.01 nM. Venetoclax induces autophagy .

HY-W727879

Upadacitinib-15N,d2

1 Publications Verification

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research .

HY-90001S

Ritonavir-d6
Ritonavir-d₆ is the deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-19569S1

Upadacitinib-d5

Upadacitinib-d₅ (ABT-494-d₅) is the deuterium labeled Upadacitinib (HY-19569). Upadacitinib (ABT-494) is a potent, orally active and selective JAK1 inhibitor (IC₅₀ = 43 nM). Upadacitinib (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib (ABT-494) can be used for several autoimmune disorders research .

HY-10087S

Navitoclax-d8 1 Publications Verification
Navitoclax-d₈ is the deuterium labeled Navitoclax. Navitoclax (ABT-263) is a potent and orally active Bcl-2 family protein inhibitor that binds to multiple anti-apoptotic Bcl-2 family proteins, such as Bcl-xL, Bcl-2 and Bcl-w, with a Ki of less than 1 nM .

HY-15531S1

Venetoclax-d6
Venetoclax-d₆ (ABT-199-d₆) is deuterium labeled Venetoclax. Venetoclax (ABT-199; GDC-0199) is a highly potent, selective and orally bioavailable Bcl-2 inhibitor with a K_i of less than 0.01 nM. Venetoclax induces autophagy .

HY-50751S

Linifanib-d4
Linifanib-d₄ (ABT-869-d₄; AL-39324-d₄) is deuterium-labeled Linifanib (HY-50751) .

HY-14814S

Delafloxacin-d5
Delafloxacin-d₅ is deuterium labeled Delafloxacin. Delafloxacin (RX-3341; WQ-3034; ABT492) is a broad-spectrum fluoroquinolone antibiotic. Delafloxacin has a broad spectrum of activity that includes drug-resistant Staphylococcus aureus, Streptococcus pneumoniae, and Klebsiella pneumonia .

HY-14588S1

Lopinavir-d8

Lopinavir-d₈ (ABT-378-d₈) is the deuterium labeled Lopinavir. Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 14.2 μM .

HY-50907S

ABT-737-d8

ABT 737-d₈ is the deuterium labeled ABT-737. ABT-737, a BH3 mimetic, is a potent Bcl-2, Bcl-x_L and Bcl-w inhibitor with EC₅₀s of 30.3 nM, 78.7 nM, and 197.8 nM, respectively. ABT-737 induces the disruption of the BCL-2/BAX complex and BAK-dependent but BIM-independent activation of the intrinsic apoptotic pathway. ABT-737 induces autophagy and has the potential for acute myeloid leukemia (AML) research .

HY-117853S

Atreleuton-d4
Atreleuton-d₄ (ABT-761-d₄; VIA-2291-d₄) is deuterium-labeled Atreleuton (HY-117853) .

HY-14588S

(rel)-Lopinavir-d8

(rel)-Lopinavir-d₈ ((rel)-ABT-378-d₈) is the deuterium labeled Lopinavir (HY-14588) . Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-14588S2

Lopinavir-d7

Lopinavir-d₇ is deuterated labeled Lopinavir (HY-14588). Lopinavir (ABT-378) is a highly potent, selective peptidomimetic inhibitor of the HIV-1 protease, with K_is of 1.3 to 3.6 pM for wild-type and mutant HIV protease. Lopinavir acts by arresting maturation of HIV-1 thereby blocking its infectivity . Lopinavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 14.2 μM .

HY-19655S

Cethromycin-d6
Cethromycin-d₆ (ABT-773-d₆; Abbott-195773-d₆; A-195773-d₆) is deuterium-labeled Cethromycin (HY-19655) .

HY-90001S3

rel-Ritonavir-d6
rel-Ritonavir-d₆ (rel-ABT 538-d₆) is the deuterium labeled rel-Ritonavir. rel-Ritonavir is a relative configuration of Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to study of HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 1.61 μM .

HY-90001S2

Ritonavir-d8
Ritonavir-d₈ is deuterated labeled Ritonavir (HY-90001). Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM.

HY-W653853

Ritonavir-13C3
Ritonavir- ¹³C₃ is ¹³C labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 1.61 μM .

HY-90001S1

Ritonavir-13C,d3
Ritonavir- ¹³C,d₃ is the ¹³C- and deuterium labeled Ritonavir. Ritonavir (ABT 538) is an inhibitor of HIV protease used to treat HIV infection and AIDS. Ritonavir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.61 μM.

Cat. No.	Product Name		Classification

HY-157745

m-PEG40000-NHS ester mPEG40000-SC; mPEG40000-Succinimidyl ester		Polymers
m-PEG-NHS ester (mPEG-SC; mPEG-Succinimidyl ester) (MW 40000) is a polyethylene glycol derivative. m-PEG-NHS ester serves as a modifying agent that reacts with free amino groups on the surface of protein or polypeptide molecules to form stable amide bonds, thereby covalently linking PEG chains to biomacromolecules, improving their antigenicity and immunogenicity, and facilitating the preparation of injectable formulations .

HY-RS00114

ABT1 Human Pre-designed siRNA Set A		siRNAs Human Pre-designed siRNA Sets
ABT1 Human Pre-designed siRNA Set A contains three designed siRNAs for ABT1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-50751G

Linifanib ABT-869; AL-39324	VEGFR PDGFR	Cancer
Linifanib (ABT-869) (GMP) is Linifanib (HY-50751) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Linifanib is a potent and orally active multi-target inhibitor of VEGFR and PDGFR family with IC₅₀s of 4, 3, 66, and 4 nM for KDR, FLT1, PDGFRβ, and FLT3, respectively. Linifanib (GMP) promotes the generation and reprogramming of iPSCs from somatic cells .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

ABT

Inhibitors & Agonists

Fluorescent Dyes

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

GMP Molecules

Natural
Products